Free Trial
OTCMKTS:TBUFF

Tribute Pharmaceuticals Canada (TBUFF) Stock Price, News & Analysis

Tribute Pharmaceuticals Canada logo

About Tribute Pharmaceuticals Canada Stock (OTCMKTS:TBUFF)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
50,100 shs
Average Volume
71,826 shs
Market Capitalization
$105.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Tribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.

Receive TBUFF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tribute Pharmaceuticals Canada and its competitors with MarketBeat's FREE daily newsletter.

TBUFF Stock News Headlines

Valeo Pharma Inc. (VPHIF)
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.
See More Headlines

TBUFF Stock Analysis - Frequently Asked Questions

Tribute Pharmaceuticals Canada Inc. (OTCMKTS:TBUFF) released its quarterly earnings results on Monday, March, 31st. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.02) by $0.01. The company earned $2.90 million during the quarter.

Shares of TBUFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
3/31/2014
Today
12/21/2024

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:TBUFF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$105.76 million
Optionable
Not Optionable
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (OTCMKTS:TBUFF) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners